What We’re Reading, July 15, 2016: What can the 7 remaining co-ops do to survive; CMS projects increased Medicare spending per enrollee by 2025; and experts call for policy changes to support the health of prisoners at high risk for HIV.
With the rapid failure of the health insurance co-ops—with 4 more announcing there are shutting doors in just the past 2 weeks—only 7 of the initial 23 will still be operational when enrollment begins in fall of this year. Survival will be the bottom line for the remaining consumer operated and oriented plans, as they are called under the Affordable Care Act, since all of them posted losses in 2015, according to Kaiser Health News. According to Timothy Jost, a law professor at Washington and Lee University in Virginia, co-ops are an important alternative to commercial insurers.
According to the CMS Office of the Actuary, the government will be spending over $10,000 a person. The study, which was published in Health Affairs, says healthcare spending will be 20% of the economy by 2025. With 1 in 5 Americans on Medicare, CMS will spend nearly $18,000 annually per member. The lead author on the study, Sean P. Keehan, an economist at the actuary’s office at CMS, told The New York Times that a significant amount of this spending would be the result of high drug prices and greater use of specialty medications.
A series of articles published in The Lancet by experts from the infectious disease field are appealing for policy changes to improve access to treatment, prevention, and care of prisoners post release—especially for those prisoners who are at a high risk of HIV infections. The articles propose solutions such as harm-reduction and drug treatment programs to reduce disease transmission.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More